Beije, N
Kraan, J
Taal, W
van der Holt, B
Oosterkamp, H M
Walenkamp, A M
Beerepoot, L
Hanse, M
van Linde, M E
Otten, A
Vernhout, R M
de Vos, F Y F
Gratama, J W
Sleijfer, S
van den Bent, M J
Article History
Received: 4 February 2015
Revised: 4 May 2015
Accepted: 10 May 2015
First Online: 4 June 2015
Competing interests
: MJvdB has done paid consultancy for Roche, Abbvie, Celldex, Amgen, and Merck Ag; has received research grants from Roche and AbbVie; and has been on the speakers' bureau for MSD. HMO has received personal fees from Roche for consultancy. The other authors declare no competing interests.